Payment overview · 2025
General Payments
$95.01
5 reported records · 4 companies
Healthcare provider profile · identity verified
Jeffrey D Wasserman, DO
Allopathic & Osteopathic Physicians|Internal Medicine · QUINCY, FL · NPI 1972507556
Verified facts
What the public records show
CMS Open Payments records show Jeffrey D Wasserman, DO received $95.01 in general payments during 2025 across 5 reported records.
GlaxoSmithKline, LLC. accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.94 | 38.9% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $21.59 | 22.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.27 | 22.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.21 | 16.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.01 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $36.94 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 930 | 251 |
| Atorvastatin Calcium | Atorvastatin Calcium | 482 | 133 |
| Metformin Hcl | Metformin Hcl | 416 | 109 |
| Lisinopril | Lisinopril | 403 | 114 |
| Omeprazole | Omeprazole | 356 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 315 | 82 |
| Potassium Chloride | Potassium Chloride | 312 | 84 |
| Famotidine | Famotidine | 288 | 69 |
| Losartan Potassium | Losartan Potassium | 271 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 261 | 74 |
| Januvia | Sitagliptin Phosphate | 217 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 55 |
| Ibuprofen | Ibuprofen | 202 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 41 |
| Doxazosin Mesylate | Doxazosin Mesylate | 199 | 44 |
| Gabapentin | Gabapentin | 182 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 52 |
| Furosemide | Furosemide | 171 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 161 | 43 |
| Clonidine Hcl | Clonidine Hcl | 157 | 36 |
| Tradjenta | Linagliptin | 157 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 148 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 32 |
| Carvedilol | Carvedilol | 137 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 36 |
| Naproxen | Naproxen | 113 | 33 |
| Alendronate Sodium | Alendronate Sodium | 111 | 29 |
| Celecoxib | Celecoxib | 110 | 35 |
| Farxiga | Dapagliflozin Propanediol | 107 | 30 |
| Allopurinol | Allopurinol | 104 | 31 |
| Indapamide | Indapamide | 103 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 27 |
| Jardiance | Empagliflozin | 100 | 21 |
| Ezetimibe | Ezetimibe | 99 | 17 |
| Ozempic | Semaglutide | 96 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 85 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 26 |
| Glimepiride | Glimepiride | 81 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 22 |
| Montelukast Sodium | Montelukast Sodium | 80 | 19 |
| Meloxicam | Meloxicam | 76 | 19 |
| Eliquis | Apixaban | 74 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 22 |
| Trazodone Hcl | Trazodone Hcl | 69 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 13 |
| Klor-Con 10 | Potassium Chloride | 57 | 16 |
| Sertraline Hcl | Sertraline Hcl | 56 | 12 |
| Simvastatin | Simvastatin | 56 | 15 |
| Pregabalin | Pregabalin | 51 | 11 |
| Alprazolam | Alprazolam | 49 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 18 |
| Metformin Hcl Er | Metformin Hcl | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 12 |
| Meclizine Hcl | Meclizine Hcl | 42 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 39 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Valsartan | Valsartan | 39 | 16 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Phenobarbital | Phenobarbital | 36 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 12 |
| Nifedipine Er | Nifedipine | 32 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Prednisone | Prednisone | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Glipizide | Glipizide | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 24 | 12 |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 17 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 11 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.01 · 5 records | GlaxoSmithKline, LLC. | ABRYSVO, BEXSERO, COMIRNATY, Ozempic, PREVNAR 20, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error